Share

July 2022; 9 (4) Research ArticleOpen Access

Transitioning From S1P Receptor Modulators to B Cell–Depleting Therapies in Multiple Sclerosis

Clinical, Radiographic, and Laboratory Data

William M. Rowles, Wan-Yu Hsu, Kira McPolin, Alyssa Li, Steven Merrill, Chu-Yueh Guo, Ari J. Green, Jeffrey Marc Gelfand, Riley M. Bove
First published May 17, 2022, DOI: https://doi.org/10.1212/NXI.0000000000001183
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
975

Share

Article Information

vol. 9 no. 4 e1183
DOI: 
https://doi.org/10.1212/NXI.0000000000001183
PubMed: 
35581005
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received May 10, 2021
  • Accepted in final form March 29, 2022
  • First Published May 17, 2022.
Copyright & Usage: 
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. William M. Rowles, BA (william.rowles{at}ucsf.edu),
    2. Wan-Yu Hsu, PhD (wan-yu.hsu{at}ucsf.edu),
    3. Kira McPolin, BA (kira.mcpolin{at}gmail.com),
    4. Alyssa Li, BA (alyssa.li{at}berkeley.edu),
    5. Steven Merrill, PharmD (steven.merrill{at}ucsf.edu),
    6. Chu-Yueh Guo, MD (chu-yueh.guo{at}ucsf.edu),
    7. Ari J. Green, MD (agreen{at}ucsf.edu),
    8. Jeffrey Marc Gelfand, MD (jeffrey.gelfand{at}ucsf.edu) and
    9. Riley M. Bove, MD, MSc
  1. William M. Rowles, BA (william.rowles{at}ucsf.edu),
  2. Wan-Yu Hsu, PhD (wan-yu.hsu{at}ucsf.edu),
  3. Kira McPolin, BA (kira.mcpolin{at}gmail.com),
  4. Alyssa Li, BA (alyssa.li{at}berkeley.edu),
  5. Steven Merrill, PharmD (steven.merrill{at}ucsf.edu),
  6. Chu-Yueh Guo, MD (chu-yueh.guo{at}ucsf.edu),
  7. Ari J. Green, MD (agreen{at}ucsf.edu),
  8. Jeffrey Marc Gelfand, MD (jeffrey.gelfand{at}ucsf.edu) and
  9. Riley M. Bove, MD, MSc
  1. From the UCSF Weill Institute for Neurosciences (W.M.R., W.-Y.H., K.M., A.L., C.-Y.G., A.J.G., J.M.G., R.M.B.), Division of Neuroimmunology and Glial Biology, Department of Neurology, Department of Clinical Pharmacy (S.M.), and UCSF Department of Ophthalmology (A.J.G.), University of California, San Francisco.
  1. Correspondence
    Dr. Bove riley.bove{at}ucsf.edu

Article usage

Article usage: May 2022 to October 2023

AbstractFullPdfSource
May 20228571185Highwire
Jun 20223315133Highwire
Jul 20229508147Highwire
Aug 20221026479Highwire
Sep 2022917745Highwire
Oct 20221813437Highwire
Nov 20223117169Highwire
Dec 2022412131Highwire
Jan 20231510932Highwire
Feb 2023913337Highwire
Mar 20231810132Highwire
Apr 2023126025Highwire
May 202398027Highwire
Jun 20231010018Highwire
Jul 202338618Highwire
Aug 202357522Highwire
Sep 202334616Highwire
Oct 202325122Highwire

Letters: Rapid online correspondence

Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me